25iP-NBOMe Stats & Data

• Microgram potency; never eyeball. Use a 0.001 g (or better) scale and volumetric dosing. NBOMe powders are too potent for typical scales; uneven blotter loading is commonly reported.

• Do not assume oral inactivity. For NBOMes, oral bioavailability can be unreliable rather than absent; delayed effects have led to hazardous redosing. Prefer buccal administration if using at all.

• Strong peripheral vasoconstriction and sympathomimetic toxicity have been repeatedly reported with NBOMes (tachycardia, hypertension, cold or numb extremities). Risk increases steeply ≥1 mg.

• Misrepresentation on LSD-style blotter is common; NBOMe tabs are typically bitter/metallic and can numb the mouth. Test blotters: Ehrlich/Hofmann positive suggests lysergamide; NBOMes do not react with Ehrlich and show distinct Marquis reactions.

• Avoid combinations with stimulants, MAOIs, DXM, or tramadol. These increase risks of hypertension, hyperthermia, seizures, and serotonin toxicity.

• Re-dosing strongly increases unpredictability, body-load, and adverse events; wait at least 3 h before concluding inactivity when identity is uncertain.

• Severe agitation, seizures, or hyperthermia require urgent medical care. First-line in hospital is supportive care with benzodiazepines and cooling; mention suspected NBOMe to clinicians.

• Nasal dosing increases speed of onset and adverse body-load; irritation and pronounced vasoconstriction are common. Avoid dry powder insufflation.

• Keep the environment cool, avoid prolonged physical exertion, and sip fluids with electrolytes to mitigate hyperthermia risk; do not overhydrate.

• People with cardiovascular disease, Raynaud’s phenomenon, or seizure history should avoid the NBOMe class entirely due to elevated risk.

• Distinguish from LSD: LSD blotter is typically nearly tasteless and fluoresces under UV; NBOMe blotters are often bitter/metallic and may not fluoresce. Always rely on reagents/drug checking, not taste alone.